BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Mar 25, 2020
Product Development

COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more

The overarching news was negative for biopharma Tuesday, with a fresh round of companies announcing trial delays. But Moderna offered a rare ray of light, hinting that its vaccine could be available sooner than many...
BC Extra | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

FDA again reviewing Immunomedics’ ADC  FDA has accepted a resubmitted BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan to treat third-line metastatic triple-negative breast cancer. The company had received a complete response...
BC Extra | Dec 20, 2019
Company News

Regulatory roundup: Gilead, BMS seeking key approvals, plus news about AbbVie, Bavarian Nordic and more

A basket of regulatory news this week included submissions of closely watched products from Gilead and BMS, including the first-ever NDA for a candidate from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Gilead Sciences Inc. (NASDAQ:GILD) is seeking...
BC Extra | Oct 25, 2019
Clinical News

Galapagos optimistic on filgotinib beyond RA, despite two misses

Galapagos remained positive on filgotinib’s development in autoimmune diseases outside of rheumatoid arthritis, despite a pair of failures in cutaneous lupus and Sjögren syndrome. “I’m personally excited about these results,” Walid Abi-Saab, CMO of Galapagos...
BC Extra | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday...
BC Extra | Aug 15, 2019
Company News

Aug. 15 Company Quick Takes: IQVia's patient portal; plus Gilead/Galapagos and GeneCentric/Select ImmunoGenomics

IQVia launches patient portal  IQVia Holdings Inc. (NYSE:IQV) launched a cloud-based patient portal designed to reduce clinical trial costs associated with patient dropout or lack of follow-up. The platform increases patient engagement with clinical guides,...
BioCentury | Jul 27, 2019
Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
BioCentury | Jul 19, 2019
Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
BC Extra | Jul 15, 2019
Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
Items per page:
1 - 10 of 111